Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Ulipristal acetate for treatment of premenstrual dysphoric disorder: A proof-of-concept randomized controlled trial
Department of Neuroscience, Science for Life Laboratory, Sweden.
Department of Clinical Sciences at Danderyd Hospital Karolinska Institutet, Department of Obstetrics and Gynecology, Danderyd Hospital, Stockholm, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Obstetrik och gynekologi.
Department of Women's and Children's Health, Karolinska Institutet, Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.
Visa övriga samt affilieringar
2021 (Engelska)Ingår i: American Journal of Psychiatry, ISSN 0002-953X, E-ISSN 1535-7228, Vol. 178, nr 3, s. 256-265Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective: Premenstrual dysphoric disorder (PMDD) is a common mood disorder, characterized by distressing affective, behavioral, and somatic symptoms in the late luteal phase of the menstrual cycle. The authors investigated continuous treatment with a selective progesterone receptor modulator, ulipristal acetate (UPA), as a potential treatment for PMDD.

Methods: The authors conducted an investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial in which women with PMDD (N=95) were treated with either 5 mg/day of UPA or placebo during three 28-day treatment cycles. The primary outcome was the change in premenstrual total score on the Daily Record of Severity of Problems (DRSP) from baseline to end of treatment. DRSP scores were captured by daily ratings using a smartphone application and were analyzed with linear mixed models for repeated measures.

Results: The mean improvement in DRSP score after 3 months was 41% (SD=18) in the UPA group, compared with 22% (SD=27) in the placebo group (mean difference 218%; 95% CI=229, 28). Treatment effects were also noted for the DRSP depressive symptom subscale (42% [SD=22] compared with 22% [SD=32]) and the DRSP anger/irritability subscale (47% [SD=21] compared with 23% [SD=35]), but not for the DRSP physical symptom subscale. Remission based on DRSP score was attained by 20 women in the UPA group (50.0%) and eight women in the placebo group (21.1%) (a statistically significant difference).

Conclusions: If these results are replicated, UPA could be a useful treatment for PMDD, particularly for the psychological symptoms associated with the disorder.

Ort, förlag, år, upplaga, sidor
2021. Vol. 178, nr 3, s. 256-265
Nationell ämneskategori
Reproduktionsmedicin och gynekologi
Identifikatorer
URN: urn:nbn:se:umu:diva-181806DOI: 10.1176/appi.ajp.2020.20030286ISI: 000624919900011Scopus ID: 2-s2.0-85102406446OAI: oai:DiVA.org:umu-181806DiVA, id: diva2:1540731
Tillgänglig från: 2021-03-30 Skapad: 2021-03-30 Senast uppdaterad: 2023-09-05Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Person

Bixo, Marie

Sök vidare i DiVA

Av författaren/redaktören
Bixo, Marie
Av organisationen
Obstetrik och gynekologi
I samma tidskrift
American Journal of Psychiatry
Reproduktionsmedicin och gynekologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 205 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf